Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 4/20 | 0.34 |
| ▸ | RARA | P10276 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19797041 | 0.90 | RARA (0.35) | FFAR4P2RY14RARBRARAPTPN11 | |
| SCHEMBL19796743 | 0.89 | PTPN11 (0.36) | P2RY14HPGDTSHRPTPN11CYP2C9 | |
| SCHEMBL19797083 | 0.88 | FFAR4 (0.42) | FFAR4RAB9AP2RY14ITGB3ITGA2B | |
| SCHEMBL19797104 | 0.87 | FFAR4 (0.36) | FFAR4RAB9AHPGDTSHRITGB3 | |
| SCHEMBL19797031 | 0.86 | FFAR4 (0.35) | FFAR4P2RY14RARBRARACYP2C9 | |
| SCHEMBL19796909 | 0.86 | FFAR4 (0.39) | FFAR4RAB9AP2RY14ITGB3ITGA2B | |
| SCHEMBL19796842 | 0.85 | RAB9A (0.38) | FFAR4RAB9AP2RY14HPGDTSHR | |
| SCHEMBL19796899 | 0.85 | THRB (0.39) | FFAR4RAB9AP2RY14HPGDTSHR | |
| SCHEMBL19796905 | 0.85 | FFAR4 (0.38) | FFAR4RAB9AHPGDTSHRITGB3 | |
| SCHEMBL19804771 | 0.85 | FFAR4 (0.48) | FFAR4RAB9ATSHRTHRBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | FFAR4 1715/4885RAB9A 4200/4885P2RY14 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.